Naxyn 500 mg

/ Teva

Rheumatic Diseases
The recommended daily dosage is 500 or 1000 mg taken as a single dose in the morning or in the evening. Alternatively, 250 or 500 mg may be taken twice daily at 12-hour intervals, morning and evening. If a dose of 250 mg is required, an alternative medical product should be considered.
In patients who tolerate lower doses well and have no history of gastrointestinal disease, the dose may be increased to 1500 mg/day for flare-ups or acute exacerbations of disease, for no longer than two weeks. Increased gastrointestinal side effects have been reported with these higher doses.
Juvenile Rheumatoid Arthritis
In children over 5 years of age: the recommended dosage is 10 mg/kg body weight per day, taken in 2 doses at 12-hour intervals. For children who, based on their weight, a dose lower than 500 mg is required, an alternative treatment should be considered.
Periarticular and Musculoskeletal Disorders
500 mg initially, followed thereafter by 250 mg at 8-12 hour intervals. For dose of 250 mg of naproxen, an alternative medical product should be considered.
Acute Gouty Arthritis
750 mg initially followed 8 hours later by 500 mg and thereafter by 250 mg 8-hourly, until the attack has passed. For doses requiring 250 mg of naproxen, an alternative medical product should be considered.
Primary Dysmenorrhea
500 mg at the onset of menstrual pain, followed by 250 mg every 6 hours until symptoms have subsided, up to a total of 1250 mg daily. For doses requiring 250 mg of naproxen, an alternative medical product should be considered.

Rheumatic diseases including osteoarthritis, ankylosing spondylitis and rheumatoid arthritis in acute flares and in long-term management, juvenile rheumatoid arthritis. Relief of pain, swelling, tenderness and fever in acute gouty arthritis, primary dysmenorrhea.

Hypersensitivity to component, syndrome of nasal polyps, angiodema, bronchospastic reactivity to aspirin or other NSAID agents, active peptic ulcer. Suppositories: In patients with history of proctitis, or inflammatory lesions of the rectum or anus, or in patients with a recent history of rectal or anal bleeding. See prescribing information for full details.

NSAID’s are not recommended in pregnancy and lactation. Risk of GI ulceration, bleeding and perforation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. Should not be administered to patients with aspirin sensitivity, use with caution in patients with pre-existing asthma. History of gastrointestinal disease, elderly and debilitated patients, liver dysfunction. Abnormal liver test has been reported. Patients with initial hemoglobin values of 10g or less who are to receive long-term therapy should have hemoglobin values determined frequently. Patients with compromised cardiac function. Ability to perform potentially-hazardous tasks may be impaired. Ophthalmological studies should be carried out within a reasonable period of time after starting naproxen therapy and repeated at periodic intervals if the drug is to be used for an extended period of time. Patients who have coagulation disorders or on full anticoagulation therapy, may be at increased risk of bleeding if given naproxen concurrently, impaired renal function, impaired hepatic function.
See prescribing information for full details.

Dizziness, abdominal pain, diarrhea, dyspepsia, flatulence.
See prescribing information for full details.

N/A.